Benralizumab — Discount Pricing

Other medications in Respiratory & Allergies

• Benzonatate
• Budesonide Nasal
• Desloratadine
• Diphenhydramine
• Dornase Alfa
• Dupilumab
• Elexacaftor-Tezacaftor-Ivacaftor
• Fluticasone Nasal

About Benralizumab

Benralizumab, known by its brand name Fasenra, is an advanced biologic medication used to treat severe eosinophilic asthma. If you or a loved one relies on this crucial treatment, understanding its role and potential costs is vital. TheDrugClub is dedicated to helping our members navigate prescription expenses, offering ways to save on essential medications like benralizumab.

Understanding Benralizumab: A Targeted Approach to Severe Asthma

Benralizumab is a targeted therapy approved for adults and adolescents aged 12 years and older as an add-on maintenance treatment for severe eosinophilic asthma. This specific type of asthma is characterized by an elevated level of eosinophils, a type of white blood cell, in the blood and airways, which contributes significantly to inflammation and asthma exacerbations. Benralizumab is not intended for the treatment of acute bronchospasm or status asthmaticus.

How Benralizumab Works to Control Your Asthma

Benralizumab is a monoclonal antibody that works by targeting the interleukin-5 receptor alpha (IL-5Rα) subunit found on the surface of eosinophils. By binding to this receptor, benralizumab initiates a process called antibody-dependent cell-mediated cytotoxicity, which leads to the rapid and nearly complete depletion of eosinophils in the blood and airways. Reducing these inflammatory cells helps to decrease the frequency of asthma attacks, improve lung function, and potentially lower the need for oral corticosteroid medication. It's a precise approach designed to address the underlying cause of inflammation in severe eosinophilic asthma.

Typical Costs of Benralizumab

As a specialized biologic medication, benralizumab typically carries a significant cost. The list price for biologic drugs can be substantial, and the final price you pay can vary widely depending on your insurance coverage, the specific pharmacy you use, and your geographic location. Without insurance, the cost of benralizumab can be very high, making it a financial challenge for many patients. Even with insurance, co-pays and deductibles can accumulate, impacting your out-of-pocket expenses.

How TheDrugClub Helps Members Save

At TheDrugClub, we understand the financial burden of managing chronic conditions like severe asthma. We work diligently

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Benralizumab is approved for (FDA label)

FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for: • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. ( 1.1 ) • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.2 ) • treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. ( 1.3 ) Limitations of Use : Not for relief of acute bronchospasm or status asthmaticus. (1.1) 1.1 Asthma FASENRA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype.

Source: Read the full FDA label on DailyMed. Label effective date: May 13, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Benralizumab (FDA label)

Injection: clear to opalescent, colorless to slightly yellow solution and may contain a few translucent or white to off‑white particles available as: • 10 mg/0.5 mL solution in a single-dose prefilled syringe. • 30 mg/mL solution in a single-dose prefilled syringe. • 30 mg/mL solution in a single-dose autoinjector FASENRA PEN. Injection: • 10 mg/0.5 mL solution in a single-dose prefilled syringe. ( 3 ) • 30 mg/mL solution in a single-dose prefilled syringe. (3) • 30 mg/mL solution in a single-dose autoinjector FASENRA PEN. (3)

Source: FDA prescribing information (DailyMed). Set ID: da6aca1a-19ed-44a4-abb7-696c7d58b784. SPL document ID: b78fbf2b-888c-41e2-bdab-cb5cd1ebb8fe. Label effective date: May 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Benralizumab (FDA label)

The following adverse reactions are described in greater detail in other sections: • Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] Most common adverse reactions (incidence greater than or equal to 5%): • Asthma: headache and pharyngitis. ( 6.1 ) • EGPA: headache. ( 6.1 ) • HES: headache, hypersensitivity reactions, and influenza-like illness. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: da6aca1a-19ed-44a4-abb7-696c7d58b784. SPL document ID: b78fbf2b-888c-41e2-bdab-cb5cd1ebb8fe. Label effective date: May 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.